Genetic Technologies

What Genetic Technologies does

Genetic Technologies (ASX: GTG) is an Australian molecular diagnostics company that provides molecular risk assessment for cancer. The company was founded in 1987, is headquartered in Fitzroy, Australia, and operates with a workforce of 51-100 employees. Its core product offering centers on genetic-based tests that evaluate an individual's risk profile for various cancers, positioning it within the personalized preventive healthcare and consumer genomics segment.

The company's go-to-market model operates through clinical and consumer channels typical of direct-to-consumer and clinician-ordered genetic testing, and it is publicly listed on the Australian Securities Exchange. The source data does not disclose specific proprietary technology platforms, named assays, or patent positions, nor does it identify specific customer logos, channel partners, or distribution agreements, which limits visibility into the underlying technical and commercial mechanics.

A notable data inconsistency is present: the company's listed website (gtglabs.com) currently displays content for what appears to be an unrelated Maroochydore, Queensland-based financial advisory firm also operating as "Genetic Technologies Limited." The structured firmographic record (ASX listing, founding year, headquarters city, employee count, and the "molecular diagnostics" descriptor) is treated as the authoritative primary description of the business. The company's 2020 capital activity consisted of two funding rounds totaling approximately $13.1 million (approximately $8 million in May 2020 and approximately $5.1 million in July 2020).

Name

Genetic Technologies

Legal name

Genetic Technologies Limited

Website

https://gtglabs.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

51–100 employees

Short description

Genetic Technologies (ASX: GTG) is an Australian molecular diagnostics company, founded in 1987 and headquartered in Fitzroy, that provides molecular risk assessment tests for cancer to individual consumers and clinicians.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Molecular diagnostics
• Cancer risk assessment
• Genetic testing
• Polygenic risk scoring
• Preventive genomics

Headquarters

HQ city

Fitzroy

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Financial Planning and Investment Advisory Services: The company generates revenue through financial planning and investment advisory services offered to individual consumers. Based on the website messaging 'Invest with Confidence' and 'Helping you plan a bright future', the business model appears to involve providing personalized investment planning services, likely on a fee-based or advisory fee structure.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Genetic Technologies is a molecular diagnostics company that performs molecular risk assessment for cancer. It delivers genetic and molecular testing services that quantify an individual's predisposition to cancer, supporting clinicians and patients in preventive health decision-making. The company generates revenue by providing these risk-assessment diagnostic services to customers across Australia.

Product overview

Genetic Technologies Limited appears to be an investment and financial planning services company based in Maroochydore, Queensland, Australia. The company's website positions itself around investment services with the tagline 'Invest with Confidence' and 'Helping you plan a bright future.' The primary offering appears to be investment planning services, though no specific named financial products or investment vehicles are detailed on the website.

Differentiator

Problem solved

Functional benefit

Products and services

• Molecular Risk Assessment for Cancer A molecular diagnostics service that assesses an individual's risk of cancer using molecular and genetic markers, delivered to clinicians and preventive health programs to support risk stratification and screening decisions.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves3 records

Expansion highlights2 records

Direct peers

• Myriad Genetics: Hereditary cancer genetic testing pioneer (BRACAnalysis, myRisk). Direct competitor in germline cancer risk assessment with established payor contracts and clinical evidence base.
• Natera: Molecular diagnostics company with oncology focus (Signatera MRD). Comparable business model of lab-developed tests serving oncologists and payors in cancer care.
• Invitae: Genetic testing company spanning hereditary cancer, reproductive health, and rare disease. Comparable in offering a multi-gene panel platform serving clinicians and patients.
• Color Genomics: Genetic testing company specialising in hereditary cancer and pharmacogenomics, with strong employer and payor channel presence. Closely comparable product set and sales motion.
• NeoGenomics: Oncology-focused clinical laboratory offering molecular and genetic testing services for cancer patients. Comparable lab operations and clinical-oncology customer base.
• Sema4: AI-driven molecular diagnostics company offering hereditary cancer and somatic tumour profiling. Closely overlaps in lab-developed oncology testing and clinician channel.

Broad incumbents

• 23andMe: DTC genetic testing provider that has expanded into health-risk reports including cancer polygenic risk scores. Larger consumer-brand competitor entering the same disease-risk testing category.
• Exact Sciences (Genomic Health): US diagnostics incumbent following Genomic Health acquisition, with Oncotype and Cologuard franchises. Comparable in oncology risk assessment though much broader in scope and scale.

Regional players

• Prenetics: Asia-Pacific headquartered genetic and consumer health testing company. Comparable genetic-testing business model with regional focus, especially Hong Kong/SEA, complementing Genetic Technologies' Australian base.

Emerging players

• Helix: Population genomics platform enabling partner-branded DNA tests including health-risk applications. Comparable as enabling infrastructure for clinical-grade genetic risk reporting.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genetic Technologies